Sanela Bilic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sanela Bilic has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Amy Place1 shared publication
- Basil T. Darras
Department of Neurology, Boston Children's Hospital, Harvard Medical School, MA
1 shared publication - Doreen Barrett1 shared publication
- George G. Nomikos
Scholar Rock, Inc., Cambridge, USA
1 shared publication - Guochen Song
BIOGEN, CAMBRIDGE, United States of America
1 shared publication - Janet O'NEil1 shared publication
Latest Publications
- Open Access
- 12 March 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (5) , e209151
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3
Background and ObjectivesCurrently approved therapies for spinal muscular atrophy (SMA) reverse the degenerative course, leading to better functional outcome, but they do not address the impairment arising from preexisting neurodegeneration. Apitegromab, ...
- 12 March 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (5) , e209151
Open AccessSafety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3
Background and ObjectivesCurrently approved therapies for spinal muscular atrophy (SMA) reverse the degenerative course, leading to better functional outcome, but they do not address the impairment arising from preexisting neurodegeneration. Apitegromab, ...
- Open Access
- 15 September 2017
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 57 (S10) , S105-S115
Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk‐Benefit Approach
Targeted therapies are now considered an integral component in the treatment armamentarium for many malignancies, and the approach to developing these drugs needs to be refined from the previous cytotoxic paradigm of toxicity-guided dose finding and identification of maximum tolerated dose to a paradigm driven by target activity. Moving away from the toxicity-driven dose finding and justification model requires an integrated approach in order to adequately characterize the risk-benefit of a drug. This approach starts with understanding the importance of collecting samples for pharmacokinetic and pharmacodynamic assessments in all phases of clinical development to fully characterize the pharmacokinetics and identify covariates and then correlating exposure to key markers of safety and efficacy in pharmacometric analyses to perform a robust risk-benefit assessment and establish the right dose. In addition, for oral agents, decisions on administering the drug with respect to food can impact dose among other clinical trial outcomes such as tolerability and patient compliance. Understanding the importance of model-based drug development as a decision-making tool to support drug development through incorporation of all relevant data allows for a robust risk-benefit assessment at key decision points. Utilization of clinical pharmacology tools and assessments throughout development will provide the key components of a successful oncology development program.
- 15 September 2017
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 57 (S10) , S105-S115
Open AccessClinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk‐Benefit Approach
Targeted therapies are now considered an integral component in the treatment armamentarium for many malignancies, and the approach to developing these drugs needs to be refined from the previous cytotoxic paradigm of toxicity-guided dose finding and identification of maximum tolerated dose to a paradigm driven by target activity. Moving away from the toxicity-driven dose finding and justification model requires an integrated approach in order to adequately characterize the risk-benefit of a drug. This approach starts with understanding the importance of collecting samples for pharmacokinetic and pharmacodynamic assessments in all phases of clinical development to fully characterize the pharmacokinetics and identify covariates and then correlating exposure to key markers of safety and efficacy in pharmacometric analyses to perform a robust risk-benefit assessment and establish the right dose. In addition, for oral agents, decisions on administering the drug with respect to food can impact dose among other clinical trial outcomes such as tolerability and patient compliance. Understanding the importance of model-based drug development as a decision-making tool to support drug development through incorporation of all relevant data allows for a robust risk-benefit assessment at key decision points. Utilization of clinical pharmacology tools and assessments throughout development will provide the key components of a successful oncology development program.